Drugs / GEO-CM04S1
GEO-CM04S1
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04639466 | Nov 2020 → Oct 2025 | COVID-19 | GeoVax, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05672355 | Aug 2023 → Jan 2029 | B-cell chronic lymphocytic leukemia, COVID-19 | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 2 | NCT04977024 | Sep 2021 → Dec 2026 expected | COVID-19, leukemia, plasma cell myeloma | GeoVax, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GEO-CM04S1 | “This phase I trial evaluates the side effects and best dose of GEO-CM04S1 (previously designated as COH04S1), a synthetic modified vaccinia Ankara (MVA)-based SARS-CoV-2...” NCT04639466 ↗ |
| Known as | COH04S1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05672355 ↗ |
| Known as | SARS-CoV-2 Vaccine COH04S1 | “SARS-CoV-2 Vaccine COH04S1” NCT05672355 ↗ |
| Known as | sMVA-based SARS-CoV-2 Vaccine COH04S1 | “sMVA-based SARS-CoV-2 Vaccine COH04S1” NCT05672355 ↗ |
| Modality | Vaccine | “GEO-CM04S1 belongs to a category called modified vaccinia Ankara (MVA) vaccines” NCT04977024 ↗ |
| Route | Intramuscular | “GEO-CM04S1 intramuscularly” NCT04639466 ↗ |